ライフサイエンスコーパス: atazanavir

1 r a boosted protease inhibitor (darunavir or atazanavir).

2 citabine plus efavirenz or ritonavir-boosted atazanavir.

3 ortant in decreasing the binding affinity of atazanavir.

4 eived at least one dose of ritonavir-boosted atazanavir.

5 aining the antiretroviral protease inhibitor atazanavir.

6 CI 1.10-1.19], p<0.0001), ritonavir-boosted atazanavir (1.20 [1.13-1.26], p<0.0001), and ritonavir-b

7 CI, 0%-3.8%) and highest for ZDV+3TC+boosted atazanavir (21.2%; 95% CI, 13.5%-30.0%).

8 , or 1200 mg once daily or ritonavir-boosted atazanavir (300 mg of atazanavir and 100 mg of ritonavir

9 Morning administration of atazanavir (300 mg once daily) and darunavir regimens ex

10 tonavir exposures, evening administration of atazanavir (300 mg) plus ritonavir (100 mg) or lopinavir

11 cell count of 225/mm(3) began treatment with atazanavir (300 mg), ritonavir (100 mg), emtricitabine (

12 Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegra

13 In these two complexes, atazanavir adopts distinct bound conformations in respon

14 Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pil

15 y or ritonavir-boosted atazanavir (300 mg of atazanavir and 100 mg of ritonavir once daily), each wit

16 = .89) (median, 69 ng/mL and 74 ng/mL in the atazanavir and darunavir arms, respectively) and were no

17 D regimen can be coadministered with morning atazanavir and darunavir regimens.

18 ynthesis of HIV protease inhibitors, such as atazanavir and darunavir.

19 ty and replication capacity was observed for atazanavir and lopinavir but not darunavir.

20 Ten-fold variation in susceptibility to PIs atazanavir and lopinavir was observed across 20 viruses,

21 and to other protease inhibitors, including atazanavir and two experimental compounds.

22 tance to lopinavir, 58% showed resistance to atazanavir, and >60% showed resistance to saquinavir, in

23 f tenofovir disoproxil fumarate, saquinavir, atazanavir, and an integrase inhibitor starting at 12 da

24 se (eg, efavirenz, lopinavir plus ritonavir, atazanavir, and darunavir).

25 darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both proteas

26 ls were tenofovir, emtricitabine, efavirenz, atazanavir, and raltegravir.

27 Tenofovir, ritonavir-boosted atazanavir, and ritonavir-boosted lopinavir use were ind

28 ibitors (ritonavir, lopinavir/ritonavir 4:1, atazanavir, atazanavir/ritonavir 4:1) or vehicle.

29 Of specific drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinav

30 004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, o

31 or 6 days and then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400

32 sus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)

33 the role of RTV in the bidirectional TVR and atazanavir (ATV) interactions.

34 Atazanavir (ATV) is a once-daily human immunodeficiency

35 substitution is observed in patients failing atazanavir (ATV) therapy.

36 fumarate/emtricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal

37 Ritonavir (RTV) and atazanavir (ATV) were co-formulated with polyvinylpyrrol

38 nocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogeni

39 ed 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (+/-) ritonavir (RTV) o

40 y virus (HIV)-infected patients receiving an atazanavir (ATV)-based antiretroviral regimen developed

41 -boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-

42 d maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucl

43 , emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plasma virus loads, bl

44 PV plus TDF (n = 301); and ritonavir-boosted atazanavir (ATZ/r) plus TDF (n = 250).

45 Structural analysis of atazanavir bound to a pretherapy B protease showed that

46 PIs (ritonavir, lopinavir, and atazanavir) but not nucleoside reverse transcriptase inh

47 Here, we show that the PIs nelfinavir and atazanavir cause cell death in various malignant glioma

48 r risk of virologic failure at 12 months for atazanavir compared with lopinavir regimens.

49 Plasma atazanavir concentrations at failure were low or below d

50 sures included HIV-1 drug resistance, plasma atazanavir concentrations, adverse events, CD4 cell coun

51 The HIV-1 PIs assessed included atazanavir, darunavir, and lopinavir (administered with

52 Atazanavir did not impact ubiquitin or proteasomal gene

53 been associated with hyperbilirubinemia and atazanavir discontinuation.

54 In a comparison with ritonavir-boosted atazanavir, efficacy and safety of BMS-663068 up to the

55 dine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293),

56 copies per mL or more and susceptibility to atazanavir, emtricitabine, and tenofovir.

57 With first-trimester atazanavir exposure, risks were highest for skin (aOR, 5

58 se was observed in successive years and with atazanavir exposure.

59 either the dolutegravir group (n=250) or the atazanavir group (n=249); two participants from each gro

60 of the 51 patients in the ritonavir-boosted atazanavir group discontinued because of adverse events.

61 group compared with 176 (71%) of 247 in the atazanavir group had HIV-1 RNA viral loads of less than

62 One participant in the atazanavir group had nucleoside reverse transcriptase in

63 ticipants in the dolutegravir group than the atazanavir group reported drug-related adverse events (8

64 dose relation and for the ritonavir-boosted atazanavir group these were mostly gastrointestinal or h

65 dolutegravir group vs 49 [20%] of 247 in the atazanavir group) and headache (28 [11%] vs 32 [13%]).

66 roxil fumarate and emtricitabine once a day (atazanavir group).

67 of the 51 patients in the ritonavir-boosted atazanavir group.

68 75%) of 51 patients in the ritonavir-boosted atazanavir group.

69 I, -.13 to 16.43) cells/microL higher in the atazanavir group.

70 27%) of 51 patients in the ritonavir-boosted atazanavir group.

71 ts were similar between the dolutegravir and atazanavir groups; the most common were nausea (46 [19%]

72 otease inhibitors (ritonavir, indinavir, and atazanavir) induce endoplasmic reticulum stress and acti

73 f its nearly symmetrical chemical structure, atazanavir is able to make several analogous contacts wi

74 ble of propagating at high-concentrations of atazanavir, lopinavir, and amprenavir (APV).

75 wed low-level cross-resistance to darunavir, atazanavir, lopinavir, and saquinavir, but not other PIs

76 00 mg once daily group) or ritonavir-boosted atazanavir (n=51).

77 As previously reported, atazanavir offers improved inhibitory profiles against s

78 nz), a ritonavir-boosted protease inhibitor (atazanavir or darunavir), or an integrase strand transfe

79 ubjects were randomized to ritonavir-boosted atazanavir or darunavir, or raltegravir-based cART.

80 ble increases in lipids observed with either atazanavir or darunavir.

81 o harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low

82 imens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleosi

83 fovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boosted lopinavir therapy.

84 a HIV-1 RNA suppressed while taking a stable atazanavir- or raltegravir-inclusive antiretroviral regi

85 hree-tablet combination of ritonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumara

86 nz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DD

87 pants with virologic failure, those assigned atazanavir plus ritonavir (ATV/r) did not have significa

88 We aimed to evaluate treatment responses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in

89 -emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral densi

90 e patients were randomly assigned to receive atazanavir plus ritonavir and 465 were assigned to recei

91 icacy was similar in the group that received atazanavir plus ritonavir and and the group that receive

92 Atazanavir plus ritonavir and efavirenz have similar ant

93 The third drugs, atazanavir plus ritonavir and efavirenz, were open-label

94 However, evening atazanavir plus ritonavir and lopinavir/ritonavir regime

95 Open-label atazanavir plus ritonavir or efavirenz, each given with

96 < 0.001) events was longer in persons given atazanavir plus ritonavir than in those given efavirenz

97 an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants

98 The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants

99 A total of 646 atazanavir/r recipients were evaluable for UGT1A1.

100 ed patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine

101 ility failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity.

102 or deaths), and 4301 individuals started an atazanavir regimen (83 deaths, 157 AIDS-defining illness

103 utegravir combined regimen compared with the atazanavir regimen support the use of dolutegravir for H

104 from the time they started a lopinavir or an atazanavir regimen.

105 as superior to that of the ritonavir-boosted atazanavir regimen.

106 for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence

107 avir, amprenavir, saquinavir, lopinavir, and atazanavir revealed that the natural polymorphisms found

108 (nanoART) through modifications of existing atazanavir, ritonavir, and efavirenz suspensions in orde

109 fovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-boosted lopinavir, other ritonavir

110 ed to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r

111 ricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-ritonavir (ATV/r).

112 est that simplified maintenance therapy with atazanavir-ritonavir alone may be efficacious for mainta

113 and 2 discontinued before simplification to atazanavir-ritonavir alone.

114 Participants switched PIs to atazanavir-ritonavir at entry and discontinued nucleosid

115 type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with t

116 ricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency v

117 proxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r

118 proxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r

119 conducted to determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretro

120 RT-naive adults with HIV initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a sing

121 IV-infected adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 8

122 onavir, lopinavir/ritonavir 4:1, atazanavir, atazanavir/ritonavir 4:1) or vehicle.

123 Seven patients discontinued atazanavir/ritonavir and 5 discontinued darunavir/ritona

124 At 96 weeks, 56 (62%) atazanavir/ritonavir and 62 (71%) darunavir/ritonavir pa

125 nce interval [CI], -.6 to 21.6) and 71 (79%) atazanavir/ritonavir and 75 (85%) darunavir/ritonavir pa

126 We found no major differences between atazanavir/ritonavir and darunavir/ritonavir in efficacy

127 .9 to 55.0; P = .0362) increased more in the atazanavir/ritonavir arm than in darunavir/ritonavir arm

128 Body fat changes in the atazanavir/ritonavir arm were associated with higher ins

129 s a greater increase in triglycerides in the atazanavir/ritonavir arm.

130 However, atazanavir/ritonavir led to higher triglycerides and mor

131 Also, fat gains with atazanavir/ritonavir were associated with insulin resist

132 al drugs (efavirenz, lopinavir/ritonavir, or atazanavir/ritonavir).

133 receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravi

134 Of specific drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavi

135 uals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted

136 isk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibi

137 ho were switched from lopinavir/ritonavir to atazanavir/ritonavir.

138 bitors, higher odds of CAs were observed for atazanavir sulfate (adjusted odds ratio [aOR], 1.95; 95%

139 cancer drug gefitinib or the retroviral drug atazanavir, the Por-deleted humanized PIRF mice develop

140 herapy B protease showed that the ability of atazanavir to maintain its binding affinity for variants

141 r [95% CI, 1.12-1.25]) and ritonavir-boosted atazanavir use (aIRR, 1.19/year [95% CI, 1.09-1.32]) wer

142 stimated the 'intention-to-treat' effect for atazanavir vs lopinavir regimens on each of the outcomes

143 djusted intention-to-treat hazard ratios for atazanavir vs lopinavir regimens were 0.70 (95% confiden

144 However, atazanavir, which does not inhibit glucose transport, ha

145 Atazanavir, which is marketed as REYATAZ, is the first h

146 tease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil f

147 rase inhibitor regimen) or ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil f

148 the X-ray crystal structures of complexes of atazanavir with two HIV-1 protease variants, namely, (i)